InMed Pharmaceuticals Inc.: management transactions · United States · SEC (Form 4)

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. is a biopharmaceutical company listed on the NASDAQ in the United States under the ticker INM. From an equity-analysis perspective, the company is best described as a development-stage biotech with a dual strategy: advancing proprietary small-molecule drug candidates for high-unmet-need diseases, while also maintaining a commercial cannabinoid business through its BayMedica segment. The company’s roots go back to 1981, when it was originally incorporated in British Columbia, and it later adopted the name InMed Pharmaceuticals Inc. in 2014 to reflect a sharper focus on cannabinoid-based pharmaceutical development. InMed’s core scientific identity is built around cannabinoid research and drug discovery. The company has long emphasized its expertise in compounds that interact with CB1 and CB2 receptors, as well as related biological targets. Its current pipeline is centered on lead assets such as INM-901, which InMed is advancing as a potential treatment for Alzheimer’s disease, and INM-089, which has been developed in an intravitreal formulation for dry age-related macular degeneration. These programs place the company squarely in the high-risk, high-reward category typical of clinical-stage biotech: valuation is driven more by scientific milestones, preclinical readouts, regulatory progress, and partnering potential than by near-term earnings. BayMedica provides a complementary commercial platform. It supplies non-intoxicating rare cannabinoids as raw materials to customers in the health and wellness market. While this business is still relatively small, it gives InMed a modest revenue stream that can help partially offset R&D spending. In the latest company disclosures, BayMedica reported annual sales of about $4.9 million for fiscal 2025, up 8% year over year. That is not enough to make the company self-funding, but it does add strategic flexibility compared with a pure pre-revenue biotech. Competitively, InMed occupies a niche position. It is not a large-cap pharmaceutical player, but it has differentiated intellectual-property and manufacturing know-how in rare cannabinoids and cannabinoid analogs. That specialization can be a source of edge if the underlying science continues to validate, yet it also means the investment case depends heavily on execution and clinical outcomes. The company’s operational footprint is associated with Vancouver, British Columbia, while its market access and investor visibility are tied to the U.S. public markets via NASDAQ in the United States. Recent news flow has been important. In 2025 and 2026, InMed highlighted progress in its development programs, including positive preclinical data for INM-901 in human brain organoid neuroinflammation models relevant to Alzheimer’s disease, and the selection of an intravitreal formulation for INM-089. The company also stated that it has strengthened its balance sheet and expects to reach additional development milestones into late 2026. Overall, InMed Pharmaceuticals is a speculative healthcare name with a focused cannabinoid platform, a small commercial revenue base, and meaningful upside potential if its pipeline advances successfully.